GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis-Reference-Cited by-同舟云学术

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis

Published:2018-03-23 Issue:7 Volume:32 Page:1631-1642
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Tefferi Ayalew,Guglielmelli Paola^ORCID,Nicolosi Maura,Mannelli Francesco,Mudireddy Mythri,Bartalucci Niccolo,Finke Christy M.,Lasho Terra L.,Hanson Curtis A.,Ketterling Rhett P.,Begna Kebede H.,Naseema Gangat ,Pardanani Animesh,Vannucchi Alessandro M.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0107-z.pdf

Reference21 articles.

1. Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L. et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–13.

2. Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 2017;129:832–7.

3. Farhadfar N, Cerquozzi S, Patnaik M, Tefferi A. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis: a practical review. J Oncol Pract. 2016;12:611–21.

4. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–901.

5. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703–8.

Cited by 225 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study;Oncohematology;2024-09-01

2. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

3. SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?;Clinical Lymphoma Myeloma and Leukemia;2024-08

4. IDH2 mutation accelerates TPO‐induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo;eJHaem;2024-07-28

5. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24